495 related articles for article (PubMed ID: 34499351)
1. Cervical cancer prevention and control in women living with human immunodeficiency virus.
Castle PE; Einstein MH; Sahasrabuddhe VV
CA Cancer J Clin; 2021 Nov; 71(6):505-526. PubMed ID: 34499351
[TBL] [Abstract][Full Text] [Related]
2. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
3. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease.
Mboumba Bouassa RS; Prazuck T; Lethu T; Jenabian MA; Meye JF; Bélec L
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):613-627. PubMed ID: 28440679
[TBL] [Abstract][Full Text] [Related]
4. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus-based cervical precancer screening with visual inspection with acetic acid triage to achieve same-day treatments among women living with human immunodeficiency virus infection: test-of-concept study in Ibadan, Nigeria.
Awolude OA; Oyerinde SO; Ayeni AO; Adewole IF
Pan Afr Med J; 2021; 40():48. PubMed ID: 34795828
[TBL] [Abstract][Full Text] [Related]
6. Prevention of Cervical Cancer in Low-Resource African Settings.
Mulongo M; Chibwesha CJ
Obstet Gynecol Clin North Am; 2022 Dec; 49(4):771-781. PubMed ID: 36328679
[TBL] [Abstract][Full Text] [Related]
7. The burden of human papillomavirus infections and related diseases in sub-saharan Africa.
De Vuyst H; Alemany L; Lacey C; Chibwesha CJ; Sahasrabuddhe V; Banura C; Denny L; Parham GP
Vaccine; 2013 Dec; 31 Suppl 5(0 5):F32-46. PubMed ID: 24331746
[TBL] [Abstract][Full Text] [Related]
8. No woman left behind: achieving cervical cancer elimination among women living with HIV.
Sharma K; Machalek DA; Toh ZQ; Amenu D; Muchengeti M; Ndlovu AK; Mremi A; Mchome B; Vallely AJ; Denny L; Rees H; Garland SM
Lancet HIV; 2023 Jun; 10(6):e412-e420. PubMed ID: 37182539
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies.
Asangbeh-Kerman SL; Davidović M; Taghavi K; Kachingwe J; Rammipi KM; Muzingwani L; Pascoe M; Jousse M; Mulongo M; Mwanahamuntu M; Tapela N; Akintade O; Basu P; Dlamini X; Bohlius J
BMC Public Health; 2022 Aug; 22(1):1530. PubMed ID: 35948944
[TBL] [Abstract][Full Text] [Related]
10. Comparison of human papillomavirus-based cervical cancer screening strategies in Tanzania among women with and without HIV.
Kahesa C; Thomsen LT; Linde DS; Mchome B; Katanga J; Swai P; Manongi R; Kjaerem M; Iftner T; Waldstrøm M; Mwaiselage J; Rasch V; Kjaer SK
Int J Cancer; 2023 Feb; 152(4):686-696. PubMed ID: 36093587
[TBL] [Abstract][Full Text] [Related]
11. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
12. [Cervical cancer: Current situation and management in Morocco].
Belglaiaa E; Mougin C
Bull Cancer; 2019 Nov; 106(11):1008-1022. PubMed ID: 31606139
[TBL] [Abstract][Full Text] [Related]
13. Elimination of cervical cancer in Tanzania: Modelled analysis of elimination in the context of endemic HIV infection and active HIV control.
Hall MT; Smith MA; Simms KT; Barnabas R; Murray JM; Canfell K
Int J Cancer; 2021 Jul; 149(2):297-306. PubMed ID: 33634857
[TBL] [Abstract][Full Text] [Related]
14. Prevention of human papillomavirus (HPV)-related tumors in people living with human immunodeficiency virus (HIV).
Poljak M; Šterbenc A; Lunar MM
Expert Rev Anti Infect Ther; 2017 Nov; 15(11):987-999. PubMed ID: 29027811
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cervical cancer.
Denny L
Reprod Health Matters; 2008 Nov; 16(32):18-31. PubMed ID: 19027619
[TBL] [Abstract][Full Text] [Related]
16. High-risk human papillomavirus in HIV-infected women undergoing cervical cancer screening in Lilongwe, Malawi: a pilot study.
Reddy D; Njala J; Stocker P; Schooley A; Flores M; Tseng CH; Pfaff C; Jansen P; Mitsuyasu RT; Hoffman RM
Int J STD AIDS; 2015 May; 26(6):379-87. PubMed ID: 24928579
[TBL] [Abstract][Full Text] [Related]
17. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential.
Sahasrabuddhe VV; Parham GP; Mwanahamuntu MH; Vermund SH
Cancer Prev Res (Phila); 2012 Jan; 5(1):11-7. PubMed ID: 22158053
[TBL] [Abstract][Full Text] [Related]
19. Cervical cancer in sub-Saharan Africa: an urgent call for improving accessibility and use of preventive services.
Dzinamarira T; Moyo E; Dzobo M; Mbunge E; Murewanhema G
Int J Gynecol Cancer; 2023 Apr; 33(4):592-597. PubMed ID: 36368710
[TBL] [Abstract][Full Text] [Related]
20. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at 1 year in women living with human immunodeficiency virus: a prospective cohort study.
Luckett R; Painter H; Hacker MR; Simon B; Seiphetlheng A; Erlinger A; Eakin C; Moyo S; Kyokunda LT; Esselen K; Feldman S; Morroni C; Ramogola-Masire D
BJOG; 2021 Nov; 128(12):1986-1996. PubMed ID: 34008294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
